European Study on Epidemiology and Management of Hepatitis C Virus (Hcv) Infection in the Haemodialysis Population Part 3: Prevalence and Incidence

Zampieron, Alessandra; Jayasekera, Heather; Elseviers, Monique; Lindley, Elizabeth; DeVos, J.-Y.; Visser, Ronald; Harrington, Maurice

doi:10.1111/j.1755-6686.2006.tb00445.x

Cited by 19 publications

(16 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2002, the prevalence of HCV infection across dialysis centers in the United States was approximately 8%1920. In some European dialysis centers, the yearly incidence of HCV infection reportedly ranges from 0.4 to 16.0%21. The prevalence of HCV infection in this study was 14.4%, which is comparable to the rates reported in previous studies.…”

Section: Discussionsupporting

confidence: 73%

Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population

Cheng

Yen

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Metabolic syndrome, an etiological factor in non-alcoholic fatty liver disease (NAFLD), is often present in hemodialysis patients. Little is known about the prevalence of, and factors associated with, liver fibrosis in hemodialysis populations. We used transient elastography (TE) to investigate these phenomena. 659 patients treated with chronic hemodialysis were enrolled. We excluded those with excess alcohol intake, liver stiffness measurement (LSM) failure, or unreliable LSM values. LSM ≥8.0 kPa was used as a cutoff suggesting clinically relevant fibrosis. Controlled attenuation parameter (CAP) ≥ 232.5 dB/m was used as a cutoff suggesting steatosis. 333 patients (50.5%) had steatosis, 159 (24.1%) had hepatitis B or C, and 149 (22.6%) had LSM ≥8.0 kPa. In multivariable analyses, male gender (OR: 2.16; 95% CI: 1.29–3.63; P = 0.004), overweight body habitus (OR:2.31; 95% CI: 1.35–3.94; P = 0.002), high AST level (OR:1.08; 95% CI: 1.04–1.12; P < 0.001), low albumin level (OR: 0.25; 95% CI: 0.12–0.53; P < 0.001), low creatinine level (OR: 0.89; 95% CI: 0.79–1.00; P = 0.05) and low platelet count (OR: 0.99; 95% CI: 0.99–1.00; P < 0.001) were associated with LSM ≥8.0 kPa. We thus conclude that hemodialysis patients have a high prevalence of NAFLD and clinically relevant fibrosis. NAFLD may be an important determinant of clinically relevant fibrosis in hemodialysis populations.

show abstract

Section: Discussionsupporting

confidence: 73%

Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population

Cheng

Yen

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Other established risk factors include excessive alcohol consumption, tobacco smoke, and dietary aflatoxin. Finland is a low risk country with very low prevalence of hepatitis B [88] and hepatitis C [89,90] infection [91], and unlike the US [89,92] there is no clear evidence for an increasing prevalence of hepatitis C infections.…”

Section: Discussionmentioning

confidence: 99%

Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland

Weiderpass

Pukkala

2006

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Given the introduction of routine screening and heightened attention to prevention of spread, the prevalence of HCV infection has declined in many dialysis centers, and yet it remains unacceptably high, ranging from 8% to 10% even in the most industrialized countries (3). In European dialysis centers the incidence rate for new-onset HCV infection varies from 0.4% (58) to 16.0% per year (59). Spontaneous disappearance of HCV RNA has been reported in 1% of untreated dialysis patients (60).…”

Section: Natural History Of Hcv Infectionmentioning

confidence: 99%

Hepatitis C Infection and Chronic Renal Diseases

Perico¹,

Cattaneo²,

Bikbov³

et al. 2009

Clinical Journal of the American Society of Nephrology

189

164

View full text Add to dashboard Cite

More than 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for over 1 million deaths resulting from cirrhosis and liver cancers. Extrahepatic manifestations are also relevant and include mixed cryoglobulinemia, lymphoproliferative disorders, and kidney disease. HCV infection is both a cause and a complication of chronic kidney disease, occurring largely in the context of mixed cryoglobulinemia. This infection also represents a major medical and epidemiologic challenge in patients with end-stage renal disease on renal replacement therapy with dialysis or transplantation. In these settings the presence of HCV correlates with higher rates of patient mortality than in HCV-negative subjects on dialysis or undergoing kidney transplant. The major concern is the lack of safe and effective drugs to treat HCV-infected patients with chronic kidney disease. Unfortunately, there are no large-scale clinical trials in this population, especially those receiving renal replacement therapy, so that strong evidence for treatment recommendations is scant. This review article provides the readers with the most recent insights on HCV infection both as cause and complication of chronic kidney disease, discusses pitfalls and limitations of current therapies, and reports on preliminary experience with novel therapeutic agents, as well as directions for future research.

show abstract

European Study on Epidemiology and Management of Hepatitis C Virus (Hcv) Infection in the Haemodialysis Population Part 3: Prevalence and Incidence

Cited by 19 publications

References 4 publications

Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population

Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population

Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland

Hepatitis C Infection and Chronic Renal Diseases

Contact Info

Product

Resources

About